CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 790 enrolled
Drug / intervention
AndroGel® (testosterone gel) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00799617
NCT00799617Phase 3Completed

Randomized, Placebo-controlled, Double-blind Study of Seven Coordinated Testosterone Treatment Trials in Older Men

University of Pennsylvania·interventional·Posted Dec 1, 2008·Updated Feb 21, 2019

In Brief

A Phase 3 clinical trial evaluating AndroGel® (testosterone gel) and Placebo for Andropause. Completed, enrolled 790 participants across 12 sites.

Detailed Summary

The Testosterone Trials are a multi-center set of trials involving 12 clinical sites geographically distributed across the United States. The primary specific aims are to test the hypotheses that testosterone treatment of elderly men whose serum testosterone concentrations are unequivocally low - and who have symptoms and objectively measured abnormalities in at least one of five areas that could be due to low testosterone (physical or sexual function, vitality, cognition, and anemia) - will result in more favorable changes in those abnormalities than placebo treatment. Two additional trials have been incorporated into the T Trial. Only men enrolled in the T Trial are eligible to participate in these trials. * The Cardiovascular Trial will examine if testosterone treatment results in more favorable changes in cardiovascular risk factors, compared to placebo. * The Bone Trial will test the hypothesis that testosterone treatment will increase volumetric trabecular bone mineral density (vBMD) of the lumbar spine as measured by quantitative computed tomography (QCT), compared with placebo treatment. A Pharmacokinetic (PK) Study is also being conducted within the context of the interventional T Trial. It will examine the variability of the serum testosterone (T) concentration after application of testosterone gel or placebo, four months after the start of treatment.

Study Details

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 1, 2008
Enrollment StartNov 1, 2009
Primary CompletionJul 1, 2014
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 17.6 years ago

Interventions

AndroGel® (testosterone gel)drug

Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.

Placebodrug

Testosterone levels will be measured at regular intervals.